The peer-reviewed published study: Duncan et al., "Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes," Obesity Pillars , 2025 (PubMed indexed)
In addition to this, in 2024, tirzepatide was accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for weight management as an adjunct to D&E in adults with a BMI 30 kg/m 2 and at least one weight-related health condition, with its use not limited to SWMS [13]
Copper induces cell death by targeting lipoylated TCA cycle proteins
GLP-1s may not be right for you if any of the following conditions apply: A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
Consider suppressive or prophylactic antiviral therapy for those with recurrent flares or severe episodes, especially if they are immunosuppressed
Semaglutide works by stimulating GLP-1 receptors in the pancreas, which increases insulin secretion when blood glucose rises and slows gastric emptying to promote satiety